Tuberculosis – Survivor Network Seeks Assurance on India’s Anti-TB Drug Supply Stability
Tuberculosis – India’s tuberculosis survivor community has sought clarity from the central government regarding the uninterrupted availability of critical anti-TB medicines and diagnostic supplies. The request comes at a time when rising geopolitical tensions in West Asia and uncertainties in global trade routes have raised concerns about potential disruptions in international medical supply chains.
Survivors’ Network Writes to Health Minister
A national network led by tuberculosis survivors has formally approached Union Health Minister JP Nadda to seek assurances about the continued supply of medicines and diagnostic consumables under the National TB Elimination Programme (NTEP).
The group, Survivors Against TB (SATB), emphasized the importance of safeguarding the availability of essential drugs and testing materials used in the treatment and detection of tuberculosis across the country.
In its communication to the ministry, the network highlighted that the current global environment is marked by unstable trade routes and geopolitical tensions, which could potentially affect the movement of pharmaceutical supplies worldwide. Given these uncertainties, the organization urged authorities to clarify whether the national programme foresees any short-term or long-term interruptions in the supply of key tuberculosis medicines.
Focus on Drug-Resistant TB Treatment
Particular concern has been raised about medicines used to treat drug-resistant forms of tuberculosis. These include treatments required for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB, which demand longer and more complex treatment regimens compared with standard TB cases.
India’s treatment protocols for such cases increasingly rely on advanced and repurposed medications, including bedaquiline, delamanid, linezolid, clofazimine, and pretomanid. These drugs form part of modern treatment combinations such as BPaL and BPaLM, which have significantly improved outcomes for patients with highly resistant strains of tuberculosis.
However, SATB noted that some of these medicines are produced through limited manufacturing partnerships or depend on a small number of international suppliers. This concentration in production could make the supply chain vulnerable if international transport or trade systems face disruptions.
Diagnostic Supplies Also Critical
Beyond medicines, the survivor network also stressed the importance of maintaining adequate stocks of diagnostic consumables used in TB detection systems. Rapid and accurate diagnosis plays a central role in controlling the spread of tuberculosis, as it enables patients to begin treatment quickly.
Testing materials used in modern diagnostic machines are often sourced through international supply channels. Any delay or shortage in these materials could slow down testing capacity, potentially delaying treatment for new patients.
To address these concerns, the network asked the government to provide details about the current status of national stockpiles, including buffer stocks maintained for both medicines and diagnostic consumables. It also requested information on contingency plans that may already be in place to handle possible disruptions.
Risks of Interrupted Treatment
Tuberculosis treatment, particularly for drug-resistant cases, requires strict adherence to medication schedules that may last several months or even longer. Interruptions during this period can lead to serious consequences.
Health experts warn that missed or incomplete treatment can result in treatment failure and may allow the bacteria to develop stronger resistance to existing medicines. Such situations not only worsen patient outcomes but also increase the risk of the disease spreading further within communities.
SATB emphasized that ensuring uninterrupted treatment is essential for the thousands of patients currently undergoing therapy for MDR and XDR tuberculosis across India.
India’s Ongoing TB Challenge
India carries one of the largest tuberculosis burdens in the world. According to estimates from the Indian Council of Medical Research, the country reports roughly 2.5 million new TB cases every year and nearly 300,000 deaths linked to the disease.
Globally, tuberculosis continues to be a major public health challenge. The World Health Organization’s latest global assessment indicates that eight countries together account for nearly two-thirds of all TB cases worldwide, with India among them.
Despite these challenges, India has set an ambitious national target to eliminate tuberculosis by 2025, five years ahead of the global goal set for 2030.
Call for Transparency and Preparedness
In its letter, the survivor network underscored the importance of transparent communication between the government and patient communities. Clear updates on medicine supply and preparedness planning, the group said, would help reassure patients currently receiving treatment and those who may begin therapy in the coming months.
The organization also reiterated its commitment to working with public health authorities to support patient-centered tuberculosis care and strengthen the national response to the disease.